MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Wearing-off fluctuations"

  • 2022 International Congress

    Gait analysis using Wearable Sensors: different gait metrics can differentiate Parkinson’s Disease Patients from Healthy Controls and Parkinson’s Disease patients in different medication status

    R. Barbosa, M. Medonça, R. Oliveira, M. Santos, A. Abreu, P. Bastos, P. Pita-Lobo, A. Valadas, L. Correia-Guedes, J. Ferreira, M. Rosa, R. Matias, M. Coelho (Lisbon, Portugal)

    Objective: To identify which gait metrics better distinguish PD-OFF from PD Best-ON and PD from HC, using a dimensionality-reduction method Background: Objective gait analysis using…
  • 2022 International Congress

    The REONPARK (REgistry of the use of COMT-inhibitors in the maNagement of patients with PARKinson’s disease in Spain who present early motor fluctuations) study: rationale and design of a national, multicentre and prospective study

    L. Lopez-Manzanares, E. Casas-Peña, I. Muro-Garcia, I. Caballero, F. Almeida, I. Tegel, P. Sarasa (Madrid, Spain)

    Objective: To describe the real-world use of catechol-O-methyltransferase (COMT) inhibitors add on to levodopa/dopa decarboxylase inhibitor (DDCI) in patients with Parkinson’s disease (PD) suffering from…
  • 2022 International Congress

    Wearing-off Questionnaire as a quantify measure of Wearing-off

    CE. Mantese, M. Medeiros, A. Schumacher-Schuh, CR. Rieder (Porto Alegre, Brazil)

    Objective: To aim for the correlation of 19- items Wearing Off Questionnaire (WOQ-19) positive items and MDS-UPDRS IV. Background: Parkinson's disease (PD) has a well…
  • 2022 International Congress

    Parkinson’s patient insights, knowledge and experience of treatment – results from a multicountry survey

    F. de Renzis, L. Graham, M. Meinders (Orpington, United Kingdom)

    Objective: To understand the perceptions and knowledge that people with Parkinson’s disease (PD) have about their treatment, available options for advanced PD, and to determine…
  • 2022 International Congress

    The effect of rasagiline on nocturnal hypokinesia: the analysis of the Nocturnal Hypokinesia Questionnaire (NHQ)

    J. Sringean, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To identify the effect of rasagiline on nocturnal hypokinesia based on Nocturnal Hypokinesia Questionnaire (NHQ). Background: Nocturnal hypokinesia refers to the difficulty or the…
  • 2022 International Congress

    Rapid onset of good ON time and improvement in motor-state stability in aPD patients after treatment with continuous subcutaneous foslevodopa/foscarbidopa

    R. Pahwa, M. Soileau, D. Standaert, V. Fung, T. Kimber, I. Malaty, A. Merola, A. Epstein, C. Yan, A. Alobaidi, A. Shewale, N. Fisseha, A. Jeong, M. Facheris, P. Kukreja, J. Zamudio, J. Aldred (Kansas City, USA)

    Objective: To evaluate time to ON without troublesome dyskinesia (‘good ON’) and patterns of motor-state stability throughout the day in patients with advanced Parkinson’s disease…
  • 2022 International Congress

    Understanding the continuing educational needs of US clinicians managing OFF episodes in Parkinson’s disease

    W. Cerenzia, S. Wiley, B. Coleman, S. Stacy, E. Jen, K. Farahmand (Birmingham, USA)

    Objective: This study sought to understand the continuing medical education (CME) needs of US-practicing neurologists (NEUROs) and neurology advanced practice providers (APPs) in managing patients with Parkinson’s Disease (PD) experiencing…
  • 2022 International Congress

    Comparison of efficacy and safety of adjunct treatments to levodopa in patients with Parkinson’s disease and wearing-off: A network meta-analysis of randomized, double-blind trials

    Y. Kogo, W. Sako, M. Koebisu, H. Yamakage, T. Ishida, N. Hattori (Tokyo, Japan)

    Objective: To determine the rankings for efficacy and tolerability of levodopa adjuncts in patients with Parkinson’s disease (PD) and wearing-off by network meta-analysis. Background: When…
  • 2022 International Congress

    Opicapone use in patients with Parkinson’s disease with motor fluctuations: experience from a tertiary center

    E. Ojeda-Lepe, L. Muñoz-Delgado, S. Jesús, AD. Adarmes-Gómez, D. Macías-García, MV. Jiménez Jaraba, B. Benítez Zamora, F. Carrillo, P. Mir (Seville, Spain)

    Objective: To assess effectiveness and safety profile of Opicapone in our cohort of patients with Parkinson’s disease (PD) who received this treatment. Background: Opicapone is…
  • 2022 International Congress

    Subgroup analyses by Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) of patients treated with levodopa inhalation powder 84mg or placebo to treat OFF symptoms in patients with Parkinson’s disease (PD)

    D. Grosset, P. Zhao, R. Marini, R. Cohen, B. Blank (Glasgow, United Kingdom)

    Objective: An analysis of the proportion of patients who turned ON after levodopa inhalation powder (CVT-301) 84mg treatment vs placebo, compared across subgroups of patients…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 26
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley